Cargando…

COVID-19 disruption to cervical cancer screening in England

INTRODUCTION: In England, routine invitations for cervical screening were reduced between April 2020 and June 2020 due to the COVID-19 pandemic. We quantify the impact of COVID-19 disruptions on attendance and excess diagnoses of cervical cancer (CC). METHODS: Using Public Health England CC screenin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Castanon, Alejandra, Rebolj, Matejka, Pesola, Francesca, Pearmain, Philippa, Stubbs, Ruth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381684/ https://www.ncbi.nlm.nih.gov/pubmed/35369792 http://dx.doi.org/10.1177/09691413221090892

Ejemplares similares

Recovery strategies following COVID-19 disruption to cervical cancer screening and their impact on excess diagnoses
por: Castanon, Alejandra, et al.
Publicado: (2021)

Is a delay in the introduction of human papillomavirus-based cervical screening affordable?
por: Castañon, Alejandra, et al.
Publicado: (2018)

Impact of changes to cervical screening guidelines on age and interval at which women are tested: Population-based study
por: Castanon, Alejandra, et al.
Publicado: (2020)

The impact of catch-up bivalent human papillomavirus vaccination on cervical screening outcomes: an observational study from the English HPV primary screening pilot
por: Rebolj, Matejka, et al.
Publicado: (2022)

A model-based analysis of the health impacts of COVID-19 disruptions to primary cervical screening by time since last screen for current and future disruptions
por: Burger, Emily A, et al.
Publicado: (2022)

Cervical screening during the COVID-19 pandemic: optimising recovery strategies
por: Castanon, Alejandra, et al.
Publicado: (2021)

Health impacts of COVID-19 disruptions to primary cervical screening by time since last screen: A model-based analysis for current and future disruptions
por: Burger, Emily A., et al.
Publicado: (2022)

Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study
por: Castanon, Alejandra, et al.
Publicado: (2017)

Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case–control study
por: Landy, Rebecca, et al.
Publicado: (2016)

Impact of screening on cervical cancer incidence in England: a time trend analysis
por: Pesola, Francesca, et al.
Publicado: (2019)

Cytology interpretation after a change to HPV testing in primary cervical screening: Observational study from the English pilot
por: Rebolj, Matejka, et al.
Publicado: (2022)

Impact of disruptions and recovery for established cervical screening programs across a range of high-income country program designs, using COVID-19 as an example: A modelled analysis
por: Smith, Megan A., et al.
Publicado: (2021)

Human Papillomavirus Testing in the Last Cervical Screening Round at Age 60–64 Years
por: Schroll, Jeppe Bennekou, et al.
Publicado: (2021)

Concurrent participation in breast, cervical, and colorectal cancer screening programmes in Denmark: A nationwide registry-based study
por: Njor, Sisse Helle, et al.
Publicado: (2023)

By how much could screening by primary human papillomavirus testing reduce cervical cancer incidence in England?
por: Castanon, Alejandra, et al.
Publicado: (2016)

Human papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: systematic review
por: Rebolj, Matejka, et al.
Publicado: (2011)

Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above
por: Rebolj, Matejka, et al.
Publicado: (2016)

Survival from Cervical Cancer Diagnosed Aged 20–29 Years by Age at First Invitation to Screening in England: Population-Based Study
por: Castanon, Alejandra, et al.
Publicado: (2020)

Adherence to follow‐up after the exit cervical cancer screening test at age 60–64: A nationwide register‐based study
por: Jørgensen, Susanne F., et al.
Publicado: (2021)

Disagreement between Human Papillomavirus Assays: An Unexpected Challenge for the Choice of an Assay in Primary Cervical Screening
por: Rebolj, Matejka, et al.
Publicado: (2014)

Is the recent increase in cervical cancer in women aged 20–24 years in England a cause for concern?
por: Castanon, Alejandra, et al.
Publicado: (2018)

Extension of cervical screening intervals with primary human papillomavirus testing: observational study of English screening pilot data
por: Rebolj, Matejka, et al.
Publicado: (2022)

Risk of cervical cancer after completed post-treatment follow-up of cervical intraepithelial neoplasia: population based cohort study
por: Rebolj, Matejka, et al.
Publicado: (2012)

Primary cervical screening with high risk human papillomavirus testing: observational study
por: Rebolj, Matejka, et al.
Publicado: (2019)

Differential Detection of Human Papillomavirus Genotypes and Cervical Intraepithelial Neoplasia by Four Commercial Assays
por: Rebolj, Matejka, et al.
Publicado: (2016)

How many preterm births in England are due to excision of the cervical transformation zone? Nested case control study
por: Wuntakal, R., et al.
Publicado: (2015)

Technological advances: Have they improved standards? Review of outcomes from the Welsh cervical screening programme
por: Castanon, Alejandra
Publicado: (2020)

Incidence of cervical cancer after several negative smear results by age 50: prospective observational study
por: Rebolj, Matejka, et al.
Publicado: (2009)

Is cervical screening preventing adenocarcinoma and adenosquamous carcinoma of the cervix?
por: Castanon, Alejandra, et al.
Publicado: (2016)

16/18 genotyping in triage of persistent human papillomavirus infections with negative cytology in the English cervical screening pilot
por: Rebolj, Matejka, et al.
Publicado: (2019)

audit_cc: A Stata command for the analysis of matched case-control audits of cervical cancer screening
por: Falcaro, Milena, et al.
Publicado: (2023)

Cervical Screening at Age 50–64 Years and the Risk of Cervical Cancer at Age 65 Years and Older: Population-Based Case Control Study
por: Castañón, Alejandra, et al.
Publicado: (2014)

Benefit of Biennial Fecal Occult Blood Screening on Colorectal Cancer in England: A Population-Based Case-Control Study
por: Castanon, Alejandra, et al.
Publicado: (2022)

Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study
por: Dillner, Joakim, et al.
Publicado: (2008)

Comparison of analytical and clinical performance of CLART HPV2 genotyping assay to Linear Array and Hybrid Capture 2: a split-sample study
por: Ejegod, Ditte Møller, et al.
Publicado: (2015)

Reply to ‘Comment on ‘Addition of ultrasound to mammography in the case of dense breast tissue: systematic review and meta-analysis”
por: Rebolj, Matejka, et al.
Publicado: (2018)

Prevalence of Human Papillomavirus in 5,072 Consecutive Cervical SurePath Samples Evaluated with the Roche Cobas HPV Real-Time PCR Assay
por: Preisler, Sarah, et al.
Publicado: (2013)

Long-term excess risk of breast cancer after a single breast density measurement
por: Rebolj, Matejka, et al.
Publicado: (2019)

Incomplete follow-up of positive HPV tests: overview of randomised controlled trials on primary cervical screening
por: Rebolj, M, et al.
Publicado: (2010)

Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data
por: Sasieni, Peter, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_s5qc7vmqov6kebt0sbtm0hief9